Related Experiment Video
Updated: Jun 27, 2025
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells
Se Young Choi1, Yunlim Kim2,3, Bumjin Lim3
1Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
Purpose:
We developed immune checkpoint molecules to target recombinant dendritic cells (DCs) and verified their anti-tumor efficacy and immune response against prostate cancer.
Materials And Methods:
DCs were generated from mononuclear cells in the tibia and femur bone marrow of mice. We knocked down the programmed death ligand 1 (PD-L1) on monocyte-derived DCs through siRNA PD-L1. Cell surface antigens were immune fluorescently stained through flow cytometry to analyze cultured cell phenotypes. Furthermore, we evaluated the efficacy of monocyte-derived DCs and recombinant DCs in a prostate cancer mouse model with subcutaneous TRAMP-C1 cells. Lastly, DC-induced mixed lymphocyte and lymphocyte-only proliferations were compared to determine cultured DCs' function.
Results:
Compared to the control group, siRNA PD-L1 therapeutic DC-treated mice exhibited significantly inhibited tumor volume and increased tumor cell apoptosis. Remarkably, this treatment substantially augmented interferon-gamma and interleukin-2 production by stimulating T-cells in an allogeneic mixed lymphocyte reaction. Moreover, we demonstrated that PD-L1 gene silencing improved cell proliferation and cytokine production.
Conclusions:
We developed monocyte-derived DCs transfected with PD-L1 siRNA from mouse bone marrow. Our study highlights that PD-L1 inhibition in DCs increases antigen-specific immune responses, corroborating previous immunotherapy methodology findings regarding castration-resistant prostate cancer.
Insights
This study shows that inhibiting programmed death ligand 1 (PD-L1) in dendritic cells (DCs) enhances anti-tumor immunity against prostate cancer. PD-L1 silencing in DCs significantly reduces tumor growth and boosts T-cell responses.
Area of Science:
- Immunotherapy
- Oncology
- Cell Biology
Background:
- Prostate cancer remains a significant health challenge, particularly castration-resistant forms.
- Dendritic cells (DCs) are crucial for initiating anti-tumor immune responses.
- Immune checkpoints, like PD-L1, can be exploited to enhance cancer immunotherapy.
Purpose of the Study:
- To develop recombinant dendritic cells (DCs) targeting immune checkpoints.
- To evaluate the anti-tumor efficacy and immune response of these modified DCs against prostate cancer.
Main Methods:
- Dendritic cells (DCs) were generated from mouse bone marrow.
- Programmed death ligand 1 (PD-L1) was knocked down using siRNA in DCs.
- Flow cytometry analyzed DC phenotypes.
- Therapeutic efficacy was assessed in a prostate cancer mouse model.
- DC function was evaluated via mixed lymphocyte reactions.
Main Results:
- Mice treated with siRNA PD-L1 DCs showed reduced tumor volume and increased apoptosis.
- This treatment significantly increased interferon-gamma and interleukin-2 production.
- PD-L1 gene silencing enhanced T-cell proliferation and cytokine production.
Conclusions:
- Monocyte-derived DCs were successfully transfected with PD-L1 siRNA.
- PD-L1 inhibition in DCs amplifies antigen-specific immune responses.
- This approach supports immunotherapy strategies for castration-resistant prostate cancer.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...